Delannoy P, Kim I, Emery N, De Bolos C, Verbert A, Degand P, Huet G
Laboratoire de Chimie Biologique, Unité Mixte de Recherche du CNRS no 111, Université des Sciences et Technologies de Lille, France.
Glycoconj J. 1996 Oct;13(5):717-26. doi: 10.1007/BF00702335.
We have analysed the mucins synthesized by the HT-29 MTX cell subpopulation, derived from the HT-29 human colon carcinoma cells through a selective pressure with methotrexate (Lesuffleur et al., 1990, Cancer Res 50: 6334-43), in the presence of benzyl-N-acetyl-alpha-galactosaminide (GalNAc alpha-O-benzyl), which is a potential competitive inhibitor of the beta 1,3-galactosyltransferase that synthesizes the T-antigen. The main observation was a 13-fold decrease in the sialic acid content of mucins after 24 h of exposure to 5 mM GalNAc alpha-O-benzyl. This effect was accompanied by an increased reactivity of these mucins to peanut lectin, testifying to the higher amount of T-antigen. The second observation was a decrease in the secretion of the mucins by GalNAc alpha-O-benzyl treated cells. The decrease in mucin sialylation was achieved through the in situ beta-galactosylation of GalNAc alpha-O-benzyl into Gal beta 1-3GalNAc alpha-O-benzyl, which acts as a competitive substrate of Gal beta 1-3GalNAc alpha 2,3-sialyltransferase, as shown by the intracellular accumulation of NeuAc alpha 2-3Gal beta 1-3GalNAc alpha-O-benzyl in treated cells.
我们分析了HT - 29 MTX细胞亚群合成的黏蛋白,该亚群是通过甲氨蝶呤的选择性压力从HT - 29人结肠癌细胞衍生而来(勒叙弗勒尔等人,1990年,《癌症研究》50: 6334 - 43),实验是在苄基 - N - 乙酰 - α - 半乳糖胺(GalNAcα - O - 苄基)存在的情况下进行的,GalNAcα - O - 苄基是合成T抗原的β1,3 - 半乳糖基转移酶的潜在竞争性抑制剂。主要观察结果是,在暴露于5 mM GalNAcα - O - 苄基24小时后,黏蛋白的唾液酸含量下降了13倍。这种效应伴随着这些黏蛋白与花生凝集素反应性的增加,证明T抗原的量增加。第二个观察结果是GalNAcα - O - 苄基处理的细胞分泌的黏蛋白减少。黏蛋白唾液酸化的减少是通过GalNAcα - O - 苄基原位β - 半乳糖基化形成Galβ1 - 3GalNAcα - O - 苄基实现的,Galβ1 - 3GalNAcα - O - 苄基作为Galβ1 - 3GalNAcα2,3 - 唾液酸转移酶的竞争性底物,这在处理过的细胞中NeuAcα2 - 3Galβ1 - 3GalNAcα - O - 苄基的细胞内积累中得到了证明。